Daniel S. Bandari

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Raju Kapoor, Pei‐Ran Ho, Nolan Campbell et al. · The Lancet Neurology · 2018 · 327 citations · Full text

Disease Progression, Neurological Disorder, Immunology +8

Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial

John Foley, Gilles Defer, Lana Zhovtis Ryerson et al. · The Lancet Neurology · 2022 · 103 citations

Relapsing-remitting Multiple Sclerosis, Clinical Neurology, Clinical Trials +8

Memantine for cognitive impairment in multiple sclerosis: a randomized placebo-controlled trial

JF Lovera, Elliot M. Frohman, TR Brown et al. · Multiple Sclerosis Journal · 2010 · 102 citations

Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial

Bruce Cree, Gary Cutter, Jerry S. Wolinsky et al. · The Lancet Neurology · 2020 · 99 citations · Full text

Assessing Quality of Life in Patients with Multiple Sclerosis

Daniel S. Bandari, Timothy Vollmer, Bhupendra Khatri et al. · International Journal of MS Care · 2010 · 48 citations · Full text

Quality Of Life, Life Assessment, Clinical Neurology +16